Nothing Special   »   [go: up one dir, main page]

Boucard et al., 2000 - Google Patents

Photolabeling identifies position 172 of the human AT1 receptor as a ligand contact point: receptor-bound angiotensin II adopts an extended structure

Boucard et al., 2000

View PDF
Document ID
16787515150467421030
Author
Boucard A
Wilkes B
Laporte S
Escher E
Guillemette G
Leduc R
Publication year
Publication venue
Biochemistry

External Links

Snippet

An angiotensin II (AngII) peptidic analogue in which the third residue (valine) was substituted with the photoreactive p-benzoyl-l-phenylalanine (Bpa) was used to identify ligand-binding sites of the human AT1 receptor. High-affinity binding of the analogue, 125I …
Continue reading at www.academia.edu (PDF) (other versions)

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
    • G01N2333/726—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans

Similar Documents

Publication Publication Date Title
Boucard et al. Photolabeling identifies position 172 of the human AT1 receptor as a ligand contact point: receptor-bound angiotensin II adopts an extended structure
Janz et al. Direct interaction between an allosteric agonist pepducin and the chemokine receptor CXCR4
Pérodin et al. Residues 293 and 294 are ligand contact points of the human angiotensin type 1 receptor
Flohr et al. Identification of nonpeptidic urotensin II receptor antagonists by virtual screening based on a pharmacophore model derived from structure− activity relationships and nuclear magnetic resonance studies on urotensin II
Cai et al. Single-cysteine substitution mutants at amino acid positions 306− 321 in rhodopsin, the sequence between the cytoplasmic end of helix VII and the palmitoylation sites: Sulfhydryl reactivity and transducin activation reveal a tertiary structure
Bolin et al. Peptide and peptide mimetic inhibitors of antigen presentation by HLA-DR class II MHC molecules. Design, structure− activity relationships, and x-ray crystal structures
Li et al. Constitutive activation of the μ opioid receptor by mutation of D3. 49 (164), but not D3. 32 (147): D3. 49 (164) is critical for stabilization of the inactive form of the receptor and for its expression
Son et al. Identification of ligand binding regions of the Saccharomyces cerevisiae α-factor pheromone receptor by photoaffinity cross-linking
Denda et al. Utilization of a soluble integrin-alkaline phosphatase chimera to characterize integrin α8β1 receptor interactions with tenascin: murine α8β1 binds to the RGD site in tenascin-C fragments, but not to native tenascin-C
Dunham et al. GPR37 surface expression enhancement via N-terminal truncation or protein− protein interactions
Greenberg et al. Mapping the Bimolecular Interface of the Parathyroid Hormone (PTH)− PTH1 Receptor Complex: Spatial Proximity between Lys27 (of the Hormone Principal Binding Domain) and Leu261 (of the First Extracellular Loop) of the Human PTH1 Receptor
Ruan et al. Solution structure of the second extracellular loop of human thromboxane A2 receptor
Shi et al. Purification and characterization of a recombinant G-protein-coupled receptor, Saccharomyces cerevisiae Ste2p, transiently expressed in HEK293 EBNA1 cells
Harikumar et al. Molecular basis of association of receptor activity-modifying protein 3 with the family BG protein-coupled secretin receptor
Umanah et al. Changes in conformation at the cytoplasmic ends of the fifth and sixth transmembrane helices of a yeast G protein-coupled receptor in response to ligand binding
Hadac et al. A peptide agonist acts by occupation of a monomeric G protein-coupled receptor: dual sites of covalent attachment to domains near TM1 and TM7 of the same molecule make biologically significant domain-swapped dimerization unlikely
Wittelsberger et al. The mid-region of parathyroid hormone (1− 34) serves as a functional docking domain in receptor activation
Wesley et al. Agonist-specific, high-affinity binding epitopes are contributed by an arginine in the N-terminus of the human oxytocin receptor
Kim et al. Identification of specific transmembrane residues and ligand-induced interface changes involved in homo-dimer formation of a yeast G protein-coupled receptor
Ho et al. Glycosylation is important for binding to human calcitonin receptors
Henry et al. Identification of a contact region between the tridecapeptide α-factor mating pheromone of Saccharomyces cerevisiae and its G protein-coupled receptor by photoaffinity labeling
Phalipou et al. Docking of linear peptide antagonists into the human V1a vasopressin receptor: Identification of binding domains by photoaffinity labeling
Hoffman et al. Structural characterization of recombinant soluble rat neuroligin 1: mapping of secondary structure and glycosylation by mass spectrometry
Schüß et al. Highly selective Y4 receptor antagonist binds in an allosteric binding pocket
Ward et al. Use of an in situ disulfide cross-linking strategy to study the dynamic properties of the cytoplasmic end of transmembrane domain VI of the M3 muscarinic acetylcholine receptor